Merck launches biosimilar version of J & J blockbuster Remicade

Merck and Co. Inc. on Monday became the second pharmaceutical company to launch a biosimilar version of Remicade, a drug that generates billions of dollars a year in sales for Johnson& Johnson. Renflexis, the Merck biosimilar product, was approved by the Food and Drug Administration on April 21 as a treatment for rheumatoid arthritis, Crohn's disease, ulcerative colitis and ankylosing spondylitis. It is the first medicine available in the United States under a global biosimilars develop ment and…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news